{"preliminary_commentary":{"by_channel":{"x_thread":9,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01339910\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"BMT CTN 0901","nct_id":"NCT01339910","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=bmt-ctn-0901-nct01339910. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.","label":"Reduced Intensity Conditioning (RIC)","type":"EXPERIMENTAL"},{"description":"One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.","label":"Myeloablative Conditioning Regimen (MAC)","type":"ACTIVE_COMPARATOR"}],"collaborators":["National Heart, Lung, and Blood Institute (NHLBI)","National Cancer Institute (NCI)","Blood and Marrow Transplant Clinical Trials Network","National Marrow Donor Program"],"completion_date":{"date":"2017-10-16","type":"ACTUAL"},"conditions":["Leukemia, Myelocytic, Acute"],"enrollment":{"count":272,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Fludarabine and Busulfan","otherNames":["Fludara and Busulfex"],"type":"DRUG"},{"name":"Fludarabine and Melphalan","otherNames":["Fludara and Alkeran"],"type":"DRUG"},{"name":"Busulfan and Fludarabine","otherNames":["Busulfex and Fludara"],"type":"DRUG"},{"name":"Busulfan and Cyclophosphamide","otherNames":["Busulfex and Cytoxan"],"type":"DRUG"},{"name":"Cyclophosphamide and Total Body Irradiation","otherNames":["Cytoxan and radiation"],"type":"DRUG"}],"last_update":"2023-01-04","lead_sponsor":"Medical College of Wisconsin","official_title":"A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (BMT CTN #0901)","overall_status":"TERMINATED","phases":["PHASE3"],"primary_completion_date":{"date":"2017-01-16","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants With Overall Survival (OS)","timeFrame":"18 months post-randomization"}],"references":[{"citation":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 Jul 30;114(5):937-51. doi: 10.1182/blood-2009-03-209262. Epub 2009 Apr 8.","pmid":"19357394","type":"BACKGROUND"},{"citation":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005 Oct 15;106(8):2912-9. doi: 10.1182/blood-2005-05-2004. Epub 2005 Jun 30.","pmid":"15994282","type":"BACKGROUND"},{"citation":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56. doi: 10.1016/j.bbmt.2005.09.004.","pmid":"16338616","type":"BACKGROUND"},{"citation":"Copelan E, Casper JT, Carter SL, van Burik JA, Hurd D, Mendizabal AM, Wagner JE, Yanovich S, Kernan NA. A scheme for defining cause of death and its application in the T cell depletion trial. Biol Blood Marrow Transplant. 2007 Dec;13(12):1469-76. doi: 10.1016/j.bbmt.2007.08.047.","pmid":"18022577","type":"BACKGROUND"},{"citation":"Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF, Alyea EP, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal AM, Horowitz MM, Deeg HJ, Horwitz ME. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol. 2017 Apr 10;35(11):1154-1161. doi: 10.1200/JCO.2016.70.7091. Epub 2017 Feb 13.","pmid":"28380315","type":"RESULT"}],"start_date":{"date":"2011-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)","url":"https://clinicaltrials.gov/study/NCT01339910"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/bmt-ctn-0901-nct01339910"}